Person who experienced the adverse event (patient)
| Event ID | CASE | I F COD | FOLL SEQ | IMAGE | EVENT DT | MFR DT | FDA DT | REPT COD | MFR NUM | MFR SNDR | AGE | AGE COD | GNDR COD | E SUB | WT | WT COD | REPT DT | OCCP COD | DEATH DT | TO MFR | CONFID | REPORTER COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6140951 | 6965777 | I | 6140951-3 | 20090217 | 20090317 | 20090331 | EXP | 2009000822 | OSI PHARMACEUTICALS | 73 | YR | M | N | 20090323 | MD | GREECE |
Drug(s) used by person
| Event ID | DRUG SEQ | ROLE COD | DRUGNAME | VAL VBM | ROUTE | DOSE VBM | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 6140951 | 1011367852 | PS | ERLOTINIB (ERLOTINIB) (TABLET) (ERLOTINIB) | 2 | ORAL | (150 MG, QD DAYS 1 TO 12), ORAL | D | D | 21743 | ||
| 6140951 | 1011408645 | SS | DOCETAXEL | 1 | INTRAVENOUS | (350 MG, DAY 15), INTRAVENOUS | |||||
| 6140951 | 1011408646 | C | MEDROL ACETATE | 1 | |||||||
| 6140951 | 1011408647 | C | ZANTAC 150 | 1 | |||||||
| 6140951 | 1011408648 | C | CETIRIZINE HCL | 1 | |||||||
| 6140951 | 1011408652 | C | LANTUS | 1 | |||||||
| 6140951 | 1011408653 | C | COAPROVEL (KARVEA HCT) | 2 |
Indications of drugs used
| Event ID | DRUG SEQ | INDI PT |
|---|---|---|
| 6140951 | 1011367852 | NON-SMALL CELL LUNG CANCER |
| 6140951 | 1011408645 | NON-SMALL CELL LUNG CANCER |
Outcome of event
| Event ID | OUTC COD |
|---|---|
| 6140951 | HO |
| 6140951 | LT |
Reactions reported
| Event ID | PT |
|---|---|
| 6140951 | ANAEMIA |
| 6140951 | INFECTION |
| 6140951 | PO2 DECREASED |
Reporting Sources (this data is often not reported and may therefore be missing here)
| Event ID | RPSR COD |
|---|---|
| 6140951 | FGN |
| 6140951 | HP |
| 6140951 | SDY |
Therapies reported
| Event ID | DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|
| 6140951 | 1011367852 | 20090114 | 20090219 | ||
| 6140951 | 1011408645 | 20090128 |